WATCHMAN FLX Device Clinical Trial Achieves Success
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BSX?
Source: Newsfilter
- Clinical Trial Results: Boston Scientific announced that the WATCHMAN FLX Left Atrial Appendage Closure device met all primary and secondary safety and efficacy endpoints in the CHAMPION-AF global clinical trial, demonstrating its superiority in patients with non-valvular atrial fibrillation.
- Bleeding Risk Reduction: The trial results indicated that the WATCHMAN FLX device had a non-procedural major and clinically relevant non-major bleeding rate of 10.9%, significantly lower than NOACs at 19.0%, achieving a 45% relative risk reduction, highlighting its advantages in bleeding management.
- Efficacy Comparison: The WATCHMAN FLX device showed a stroke, cardiovascular or unexplained death, and systemic embolism occurrence rate of 5.7%, compared to 4.8% for NOACs, demonstrating statistical non-inferiority and reinforcing its potential as a first-line treatment option.
- Global Impact: This trial is the largest comparison of an LAAC device to NOACs to date, involving 141 sites and achieving a 99% procedural success rate, providing robust support for future updates to clinical guidelines.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 70.170
Low
94.00
Averages
108.14
High
132.00
Current: 70.170
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
WATCHMAN FLX Device Clinical Trial Achieves Success
- Clinical Trial Success: Boston Scientific announced that its WATCHMAN FLX device successfully met all primary and secondary safety and efficacy endpoints in the CHAMPION-AF global clinical trial, demonstrating similar efficacy to anticoagulants in patients with non-valvular atrial fibrillation, potentially transforming stroke risk reduction treatment strategies.
- Bleeding Risk Comparison: The trial results indicated a major bleeding event rate of 5.9% for the WATCHMAN FLX device at 36 months, statistically non-inferior to the 6.4% rate for anticoagulants (P<0.001), providing strong support for its use as a first-line treatment option.
- Broad Applicability: The CHAMPION-AF trial is the largest study to date comparing LAAC devices to anticoagulants, involving 3,000 patients from 141 sites, with a 99% procedural success rate, showcasing the device's broad applicability and reliability.
- Future Outlook: Boston Scientific plans to leverage these positive data to support updates to global clinical guidelines and expand indications for the WATCHMAN platform, aiming to provide more treatment options for a growing number of atrial fibrillation patients and reduce stroke risk.
See More
WATCHMAN FLX Device Clinical Trial Achieves Success
- Clinical Trial Results: Boston Scientific announced that the WATCHMAN FLX Left Atrial Appendage Closure device met all primary and secondary safety and efficacy endpoints in the CHAMPION-AF global clinical trial, demonstrating its superiority in patients with non-valvular atrial fibrillation.
- Bleeding Risk Reduction: The trial results indicated that the WATCHMAN FLX device had a non-procedural major and clinically relevant non-major bleeding rate of 10.9%, significantly lower than NOACs at 19.0%, achieving a 45% relative risk reduction, highlighting its advantages in bleeding management.
- Efficacy Comparison: The WATCHMAN FLX device showed a stroke, cardiovascular or unexplained death, and systemic embolism occurrence rate of 5.7%, compared to 4.8% for NOACs, demonstrating statistical non-inferiority and reinforcing its potential as a first-line treatment option.
- Global Impact: This trial is the largest comparison of an LAAC device to NOACs to date, involving 141 sites and achieving a 99% procedural success rate, providing robust support for future updates to clinical guidelines.
See More
Boston Scientific's EKOS Device Shows Positive Clinical Trial Results
- Clinical Trial Results: Boston Scientific's HI-PEITHO global randomized trial demonstrated that the EKOS™ system combined with anticoagulation significantly reduced primary endpoint event rates from 10.3% to 4.0%, achieving a 61% risk reduction, marking a new standard for acute pulmonary embolism treatment.
- Patient Recruitment: The trial enrolled 544 patients with intermediate-risk PE across 59 sites in the U.S. and Europe, ensuring broad data representation and providing a solid foundation for clinical decision-making.
- Safety and Hospitalization: The EKOS system not only did not increase the risk of major bleeding but also significantly shortened hospital stays, enhancing the overall treatment experience for patients and demonstrating its safety and efficacy in clinical applications.
- Future Treatment Direction: The trial results provide strong data support for interventionalists and referring physicians, promoting the EKOS plus anticoagulation therapy as a first-line treatment for acute pulmonary embolism, indicating a shift in future treatment strategies.
See More
EKOS System Shows Superiority in Treating Acute Pulmonary Embolism
- Clinical Trial Results: The HI-PEITHO global randomized trial demonstrated that the EKOS system combined with anticoagulation achieved a primary endpoint event rate of 4.0% in intermediate-risk PE patients, significantly lower than the 10.3% rate for anticoagulation alone, indicating a 61% reduction in events and underscoring the clinical efficacy of the EKOS system.
- Shorter Hospital Stay: Patients treated with the EKOS system experienced no brain bleeding incidents and had a significantly shorter hospital stay compared to those receiving only anticoagulation, which not only reduces healthcare costs but also enhances the overall treatment experience for patients.
- Patient Recruitment and Collaboration: The trial enrolled 544 intermediate-risk PE patients across 59 sites in the U.S. and Europe, showcasing Boston Scientific's collaboration with the PERT Consortium and the University Medical Center Mainz, which advances research in pulmonary embolism treatment.
- Clinical Application Prospects: The findings provide crucial randomized clinical trial data for interventionalists and referring physicians, supporting the consideration of the EKOS system plus anticoagulation as a first-line therapy for acute pulmonary embolism, indicating significant future application potential in the cardiovascular field.
See More
WATCHMAN FLX Device Clinical Trial Achieves Success
- Clinical Trial Results: Boston Scientific announced that the CHAMPION-AF global clinical trial successfully met all primary and secondary safety and efficacy endpoints, demonstrating that the WATCHMAN FLX device offers superior bleeding protection compared to traditional anticoagulants in patients with non-valvular atrial fibrillation, marking a significant clinical milestone.
- Bleeding Risk Reduction: The WATCHMAN FLX device achieved a primary safety endpoint at 36 months, showing a non-procedural major and clinically relevant non-major bleeding rate of 10.9%, significantly lower than NOACs at 19.0%, resulting in a 45% relative risk reduction, highlighting its advantages in bleeding management.
- Efficacy Comparison: In terms of efficacy, the WATCHMAN FLX device recorded a stroke, cardiovascular or unexplained death, and systemic embolism rate of 5.7%, demonstrating statistical non-inferiority compared to NOACs at 4.8%, further solidifying its potential as a first-line treatment option.
- Global Impact: This trial is the largest comparison of LAAC devices to NOACs to date, involving 141 sites with a 99% procedural success rate, establishing a strong foundation for the promotion of the WATCHMAN FLX device and is expected to drive updates in global clinical guidelines.
See More
Boston Scientific's EKOS Device Shows Positive Clinical Trial Results
- Clinical Trial Results: Boston Scientific's HI-PEITHO global randomized trial demonstrated that the EKOS™ system combined with anticoagulation significantly reduced clinical event rates in acute pulmonary embolism patients, achieving a 61% reduction with rates of 4.0% versus 10.3% (P=0.005).
- Safety and Hospital Stay: The trial results indicated that the use of the EKOS system did not increase the risk of major bleeding and also shortened hospital stays, enhancing the clinical benefits of the treatment while aligning with current medical management standards.
- Patient Recruitment and Scale: The HI-PEITHO trial enrolled 544 intermediate-risk PE patients across 59 sites in the U.S. and Europe, ensuring the broad applicability and clinical significance of the findings.
- Future Treatment Guidance: This study provides robust randomized clinical trial data to inform interventionalists and referring physicians, supporting the consideration of EKOS plus anticoagulation as a first-line therapy for acute pulmonary embolism, potentially changing existing treatment standards.
See More
WATCHMAN FLX Device Clinical Trial Achieves Success
- Clinical Trial Success: Boston Scientific announced that its WATCHMAN FLX device successfully met all primary and secondary safety and efficacy endpoints in the CHAMPION-AF global clinical trial, demonstrating similar efficacy to anticoagulants in patients with non-valvular atrial fibrillation, potentially transforming stroke risk reduction treatment strategies.
- Bleeding Risk Comparison: The trial results indicated a major bleeding event rate of 5.9% for the WATCHMAN FLX device at 36 months, statistically non-inferior to the 6.4% rate for anticoagulants (P<0.001), providing strong support for its use as a first-line treatment option.
- Broad Applicability: The CHAMPION-AF trial is the largest study to date comparing LAAC devices to anticoagulants, involving 3,000 patients from 141 sites, with a 99% procedural success rate, showcasing the device's broad applicability and reliability.
- Future Outlook: Boston Scientific plans to leverage these positive data to support updates to global clinical guidelines and expand indications for the WATCHMAN platform, aiming to provide more treatment options for a growing number of atrial fibrillation patients and reduce stroke risk.
See More
WATCHMAN FLX Device Clinical Trial Achieves Success
- Clinical Trial Results: Boston Scientific announced that the WATCHMAN FLX Left Atrial Appendage Closure device met all primary and secondary safety and efficacy endpoints in the CHAMPION-AF global clinical trial, demonstrating its superiority in patients with non-valvular atrial fibrillation.
- Bleeding Risk Reduction: The trial results indicated that the WATCHMAN FLX device had a non-procedural major and clinically relevant non-major bleeding rate of 10.9%, significantly lower than NOACs at 19.0%, achieving a 45% relative risk reduction, highlighting its advantages in bleeding management.
- Efficacy Comparison: The WATCHMAN FLX device showed a stroke, cardiovascular or unexplained death, and systemic embolism occurrence rate of 5.7%, compared to 4.8% for NOACs, demonstrating statistical non-inferiority and reinforcing its potential as a first-line treatment option.
- Global Impact: This trial is the largest comparison of an LAAC device to NOACs to date, involving 141 sites and achieving a 99% procedural success rate, providing robust support for future updates to clinical guidelines.
See More
Boston Scientific's EKOS Device Shows Positive Clinical Trial Results
- Clinical Trial Results: Boston Scientific's HI-PEITHO global randomized trial demonstrated that the EKOS™ system combined with anticoagulation significantly reduced primary endpoint event rates from 10.3% to 4.0%, achieving a 61% risk reduction, marking a new standard for acute pulmonary embolism treatment.
- Patient Recruitment: The trial enrolled 544 patients with intermediate-risk PE across 59 sites in the U.S. and Europe, ensuring broad data representation and providing a solid foundation for clinical decision-making.
- Safety and Hospitalization: The EKOS system not only did not increase the risk of major bleeding but also significantly shortened hospital stays, enhancing the overall treatment experience for patients and demonstrating its safety and efficacy in clinical applications.
- Future Treatment Direction: The trial results provide strong data support for interventionalists and referring physicians, promoting the EKOS plus anticoagulation therapy as a first-line treatment for acute pulmonary embolism, indicating a shift in future treatment strategies.
See More
EKOS System Shows Superiority in Treating Acute Pulmonary Embolism
- Clinical Trial Results: The HI-PEITHO global randomized trial demonstrated that the EKOS system combined with anticoagulation achieved a primary endpoint event rate of 4.0% in intermediate-risk PE patients, significantly lower than the 10.3% rate for anticoagulation alone, indicating a 61% reduction in events and underscoring the clinical efficacy of the EKOS system.
- Shorter Hospital Stay: Patients treated with the EKOS system experienced no brain bleeding incidents and had a significantly shorter hospital stay compared to those receiving only anticoagulation, which not only reduces healthcare costs but also enhances the overall treatment experience for patients.
- Patient Recruitment and Collaboration: The trial enrolled 544 intermediate-risk PE patients across 59 sites in the U.S. and Europe, showcasing Boston Scientific's collaboration with the PERT Consortium and the University Medical Center Mainz, which advances research in pulmonary embolism treatment.
- Clinical Application Prospects: The findings provide crucial randomized clinical trial data for interventionalists and referring physicians, supporting the consideration of the EKOS system plus anticoagulation as a first-line therapy for acute pulmonary embolism, indicating significant future application potential in the cardiovascular field.
See More
WATCHMAN FLX Device Clinical Trial Achieves Success
- Clinical Trial Results: Boston Scientific announced that the CHAMPION-AF global clinical trial successfully met all primary and secondary safety and efficacy endpoints, demonstrating that the WATCHMAN FLX device offers superior bleeding protection compared to traditional anticoagulants in patients with non-valvular atrial fibrillation, marking a significant clinical milestone.
- Bleeding Risk Reduction: The WATCHMAN FLX device achieved a primary safety endpoint at 36 months, showing a non-procedural major and clinically relevant non-major bleeding rate of 10.9%, significantly lower than NOACs at 19.0%, resulting in a 45% relative risk reduction, highlighting its advantages in bleeding management.
- Efficacy Comparison: In terms of efficacy, the WATCHMAN FLX device recorded a stroke, cardiovascular or unexplained death, and systemic embolism rate of 5.7%, demonstrating statistical non-inferiority compared to NOACs at 4.8%, further solidifying its potential as a first-line treatment option.
- Global Impact: This trial is the largest comparison of LAAC devices to NOACs to date, involving 141 sites with a 99% procedural success rate, establishing a strong foundation for the promotion of the WATCHMAN FLX device and is expected to drive updates in global clinical guidelines.
See More
Boston Scientific's EKOS Device Shows Positive Clinical Trial Results
- Clinical Trial Results: Boston Scientific's HI-PEITHO global randomized trial demonstrated that the EKOS™ system combined with anticoagulation significantly reduced clinical event rates in acute pulmonary embolism patients, achieving a 61% reduction with rates of 4.0% versus 10.3% (P=0.005).
- Safety and Hospital Stay: The trial results indicated that the use of the EKOS system did not increase the risk of major bleeding and also shortened hospital stays, enhancing the clinical benefits of the treatment while aligning with current medical management standards.
- Patient Recruitment and Scale: The HI-PEITHO trial enrolled 544 intermediate-risk PE patients across 59 sites in the U.S. and Europe, ensuring the broad applicability and clinical significance of the findings.
- Future Treatment Guidance: This study provides robust randomized clinical trial data to inform interventionalists and referring physicians, supporting the consideration of EKOS plus anticoagulation as a first-line therapy for acute pulmonary embolism, potentially changing existing treatment standards.
See More
